A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations

DOI10.1002/BIMJ.201900095zbMath1448.62173arXiv1809.04348OpenAlexW3100833846WikidataQ90158506 ScholiaQ90158506MaRDI QIDQ5135528

J. L. Jiménez, Sungjin Kim, Mourad Tighiouart

Publication date: 23 November 2020

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: https://arxiv.org/abs/1809.04348

zbMATH Keywords

adaptive randomizationtwo-stage designsescalation with overdose controlcontinuous dosesdrug combinations

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (1)

Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information

This page was built for publication: A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations